|
1
|
Tamimi AF and Juweid M: Epidemiology and
outcome of glioblastoma. In: Glioblastoma. De Vleeschouwer S (ed).
Codon Publications, Brisbane, AU, 2017.
|
|
2
|
Batash R, Asna N, Schaffer P, Francis N
and Schaffer M: Glioblastoma multiforme, diagnosis and treatment;
recent literature review. Curr Med Chem. 24:3002–3009.
2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: A clinical review. JAMA. 310:1842–1850.
2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48.
2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Dréan A, Goldwirt L, Verreault M, Canney
M, Schmitt C, Guehennec J, Delattre JY, Carpentier A and Idbaih A:
Blood-brain barrier, cytotoxic chemotherapies and glioblastoma.
Expert Rev Neurother. 16:1285–1300. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Schaff LR and Mellinghoff IK: Glioblastoma
and other primary brain malignancies in adults: A review. JAMA.
329:574–587. 2023.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Fang XH, Zou MY, Chen FQ, Ni H, Nie SP and
Yin JY: An overview on interactions between natural product-derived
β-glucan and small-molecule compounds. Carbohydr Polym.
261(117850)2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
McKinnon C, Nandhabalan M, Murray SA and
Plaha P: Glioblastoma: Clinical presentation, diagnosis, and
management. BMJ. 374(n1560)2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
An YL, Wei WL and Guo DA: Application of
analytical technologies in the discrimination and authentication of
herbs from Fritillaria: A review. Crit Rev Anal Chem. 54:1775–1796.
2024.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Yi PF, Wu YC, Dong HB, Guo Y, Wei Q, Zhang
C, Song Z, Qin QQ, Lv S, Wu SC and Fu BD: Peimine impairs
pro-inflammatory cytokine secretion through the inhibition of the
activation of NF-κB and MAPK in LPS-induced RAW264.7 macrophages.
Immunopharmacol Immunotoxicol. 35:567–572. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Xu J, Zhao W, Pan L, Zhang A, Chen Q, Xu
K, Lu H and Chen Y: Peimine, a main active ingredient of
Fritillaria, exhibits anti-inflammatory and pain suppression
properties at the cellular level. Fitoterapia. 111:1–6.
2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhang L, Cui M and Chen S: Identification
of the molecular mechanisms of peimine in the treatment of cough
using computational target fishing. Molecules.
25(1105)2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhang T, Liu GY, Cao JL, Li YN, Xue H, Wu
HT and Jin CH: Peimine-induced apoptosis and inhibition of
migration by regulating reactive oxygen species-mediated
MAPK/STAT3/NF-κB and Wnt/β-catenin signaling pathways in gastric
cancer MKN-45 cells. Drug Dev Res. 83:1683–1696. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Sun J, Li J, Kong X and Guo Q: Peimine
inhibits MCF-7 breast cancer cell growth by modulating inflammasome
activation: Critical roles of MAPK and NF-κB signaling. Anticancer
Agents Med Chem. 23:317–327. 2023.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tan H, Zhang G, Yang X, Jing T, Shen D and
Wang X: Peimine inhibits the growth and motility of prostate cancer
cells and induces apoptosis by disruption of intracellular calcium
homeostasis through Ca2+/CaMKII/JNK pathway. J Cell
Biochem. 121:81–92. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chen J, Yu Y, Li H, Hu Q, Chen X, He Y,
Xue C, Ren F, Ren Z, Li J, et al: Long non-coding RNA PVT1 promotes
tumor progression by regulating the miR-143/HK2 axis in gallbladder
cancer. Mol Cancer. 18(33)2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Chen K, Lv ZT, Zhou CH, Liang S, Huang W,
Wang ZG, Zhu WT, Wang YT, Jing XZ, Lin H, et al: Peimine suppresses
interleukin-1β-induced inflammation via MAPK downregulation in
chondrocytes. Int J Mol Med. 43:2241–2251. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Tanaka S, Louis DN, Curry WT, Batchelor TT
and Dietrich J: Diagnostic and therapeutic avenues for
glioblastoma: No longer a dead end? Nat Rev Clin Oncol. 10:14–26.
2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Le Rhun E, Preusser M, Roth P, Reardon DA,
van den Bent M, Wen P, Reifenberger G and Weller M: Molecular
targeted therapy of glioblastoma. Cancer Treat Rev.
80(101896)2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhao W, Zheng XD, Tang PY, Li HM, Liu X,
Zhong JJ and Tang YJ: Advances of antitumor drug discovery in
traditional Chinese medicine and natural active products by using
multi-active components combination. Med Res Rev. 43:1778–1808.
2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Sevastre AS, Costachi A, Tataranu LG,
Brandusa C, Artene SA, Stovicek O, Alexandru O, Danoiu S, Sfredel V
and Dricu A: Glioblastoma pharmacotherapy: A multifaceted
perspective of conventional and emerging treatments (review). Exp
Ther Med. 22(1408)2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wang W, Yuan X, Mu J, Zou Y, Xu L, Chen J,
Zhu X, Li B, Zeng Z, Wu X, et al: Quercetin induces
MGMT+ glioblastoma cells apoptosis via dual inhibition
of Wnt3a/β-catenin and Akt/NF-κB signaling pathways. Phytomedicine.
118(154933)2023.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Shen J, Zhang T, Cheng Z, Zhu N, Wang H,
Lin L, Wang Z, Yi H and Hu M: Lycorine inhibits glioblastoma
multiforme growth through EGFR suppression. J Exp Clin Cancer Res.
37(157)2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Luo H, Vong CT, Chen H, Gao Y, Lyu P, Qiu
L, Zhao M, Liu Q, Cheng Z, Zou J, et al: Naturally occurring
anti-cancer compounds: Shining from Chinese herbal medicine. Chin
Med. 14(48)2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhao L, Zhang H, Li N, Chen J, Xu H, Wang
Y and Liang Q: Network pharmacology, a promising approach to reveal
the pharmacology mechanism of Chinese medicine formula. J
Ethnopharmacol. 309(116306)2023.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hussain A, Brahmbhatt K, Priyani A, Ahmed
M, Rizvi TA and Sharma C: Eugenol enhances the chemotherapeutic
potential of gemcitabine and induces anticarcinogenic and
anti-inflammatory activity in human cervical cancer cells. Cancer
Biother Radiopharm. 26:519–527. 2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Liu Y, Yang S, Wang K, Lu J, Bao X, Wang
R, Qiu Y, Wang T and Yu H: Cellular senescence and cancer: Focusing
on traditional Chinese medicine and natural products. Cell Prolif.
53(e12894)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wang X, Li J, Chen R, Li T and Chen M:
Active ingredients from Chinese medicine for combination cancer
therapy. Int J Biol Sci. 19:3499–3525. 2023.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhang P, Jiang Y, Ye X, Zhang C and Tang
Y: PDK1 inhibition reduces autophagy and cell senescence through
the PI3K/AKT signalling pathway in a cigarette smoke mouse
emphysema model. Exp Ther Med. 25(223)2023.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wong RS: Apoptosis in cancer: From
pathogenesis to treatment. J Exp Clin Cancer Res.
30(87)2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wu Y, Chang J, Ge J, Xu K, Zhou Q, Zhang
X, Zhu N and Hu M: Isobavachalcone's alleviation of pyroptosis
contributes to enhanced apoptosis in glioblastoma: Possible
involvement of NLRP3. Mol Neurobiol. 59:6934–6955. 2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Bertheloot D, Latz E and Franklin BS:
Necroptosis, pyroptosis and apoptosis: An intricate game of cell
death. Cell Mol Immunol. 18:1106–1121. 2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ketelut-Carneiro N and Fitzgerald KA:
Apoptosis, pyroptosis, and necroptosis-oh my! The many ways a cell
can die. J Mol Biol. 434(167378)2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Attwaters M: Persisting through apoptosis.
Nat Rev Mol Cell Biol. 23(697)2022.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Newton K, Strasser A, Kayagaki N and Dixit
VM: Cell death. Cell. 187:235–256. 2024.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Zhang L, Liu Z, Dong Y and Kong L: E2F2
drives glioma progression via PI3K/AKT in a PFKFB4-dependent
manner. Life Sci. 276(119412)2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Chautard E, Ouédraogo ZG, Biau J and
Verrelle P: Role of Akt in human malignant glioma: From oncogenesis
to tumor aggressiveness. J Neurooncol. 117:205–215. 2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zhang X, Li Z, Wei C, Luo L, Li S, Zhou J,
Liang H, Li Y and Han L: PLK4 initiates crosstalk between cell
cycle, cell proliferation and macrophages infiltration in gliomas.
Front Oncol. 12(1055371)2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Liu F, Chen G, Zhou LN, Wang Y, Zhang ZQ,
Qin X and Cao C: YME1L overexpression exerts pro-tumorigenic
activity in glioma by promoting Gαi1 expression and Akt activation.
Protein Cell. 14:223–229. 2023.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Ren J, Zheng S, Zhang L, Liu J, Cao H, Wu
S, Xu Y and Sun J: MAPK4 predicts poor prognosis and facilitates
the proliferation and migration of glioma through the AKT/mTOR
pathway. Cancer Med. 12:11624–11640. 2023.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Tang YQ, Li ZW, Feng YF, Yang HQ, Hou CL,
Geng C, Yang PR, Zhao HM and Wang J: MK2206 attenuates
atherosclerosis by inhibiting lipid accumulation, cell migration,
proliferation, and inflammation. Acta Pharmacol Sin. 43:897–907.
2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Xiang RF, Wang Y, Zhang N, Xu WB, Cao Y,
Tong J, Li JM, Wu YL and Yan H: MK2206 enhances the cytocidal
effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR
pathway. Cell Death Dis. 8(e2776)2017.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Cui X, Zhao J, Li G, Yang C, Yang S, Zhan
Q, Zhou J, Wang Y, Xiao M, Hong B, et al: Blockage of EGFR/AKT and
mevalonate pathways synergize the antitumor effect of temozolomide
by reprogramming energy metabolism in glioblastoma. Cancer Commun
(Lond). 43:1326–1353. 2023.PubMed/NCBI View Article : Google Scholar
|
